Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.
Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE). A poster presented at the American Society of Hematology annual meeting found that the most common treatment remains parenteral anticoagulant (PAC) with warfarin despite the arrival of a the new treatment option rivaroxaban.
Researchers from Boston Health Economics Inc, and Boehringer Ingelheim Pharmaceuticals, Inc, studied hospital administrative claims data from more than 600 hospitals for patients age 18 years or older who had a primary discharge diagnosis of DVT and/or PE in order to evaluate characteristics and treatment patterns.
“Given the relatively recent introduction of novel oral anticoagulants (NOACs), it is essential to understand the demographic and clinical characteristics of DVT/PE patients receiving these therapies,” the authors wrote.
The study included 46,214 patients with 54% receiving the primary diagnosis of PE, 38% receiving the diagnosis of DVT without PE, and 8% receiving the diagnosis of DVT with secondary PE.
The most common treatment was PAC and warfarin (70%), followed by PAC alone (16%), then PAC and rivaroxaban (6%), PAC and warfarin and rivaroxaban (4%), wafarin alone (1%), rivaroxaban (1%), and no anticoagulant treatment (2%).
Using a logistic regression, the researchers determined that patients with a primary PE diagnosis, a primary DVT diagnosis with a secondary PE diagnosis, receipt of thrombolytic drugs, the presence of renal disease, and receipt of care in an urban hospital were significantly more likely to receive rivaroxaban with PAC and/or warfarin compared to rivaroxaban alone.
“Our findings indicate that the standard of care (PAC + warfarin) remains the dominant treatment regimen despite the availability of newer NOACs,” the authors concluded. “Future studies of treated patients with DVT and/or PE should examine whether these preliminary observations of treatment patterns change with increased clinical experience with NOACs.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More